1. 2022-RA-464-ESGO A phase i dose escalation and expansion cohort trial of carboplatin and gemcitabine with the ATR inhibitor berzosertib in first or second recurrence platinum sensitive epithelial ovarian, peritoneal, and fallopian tube cancer. (20th October 2022) Authors: Wahner Hendrickson, Andrea E; Foster, Nathan; Corr, Bradley R; Duska, Linda; Markham, Merry J; Butler, Kristina; Girda, Eugenia; Miller, Rachel Ware; Arneson, Katherine; Gano, Katherine; Johnson, Janelle; Shapiro, Geoffrey; Rubinstein, Larry; Percy Ivy, S; Kohn, Elise; Adjei, Alex; Kaufmann, Scott Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. (11th November 2019) Authors: Arrillaga-Romany, Isabel; Sahebjam, Solmaz; Picconi, David; Campian, Jian; Giglio, Pierre; Drappatz, Jan; Aiken, Robert; Villano, John; Lee, Eudocia; Welch, Mary; Ellingson, Benjamin; Ney, Douglas; Becker, Kevin; Muzikansky, Alona; Das, Biswajit; Swisher, Elizabeth; Nixon, Andrew; Karlovich, Chri... Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗